SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2026 / Volume: 4 Special Issue

Cetuximab-Induced Acneiform Eruption: A Case Report

Büşra Güner(ULUDAĞ ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ ENSTİTÜSÜ, İÇ HASTALIKLARI (DR))0000-0001-6320-9512
Sibel Oyucu Orhan(ULUDAĞ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, TIBBİ ONKOLOJİ BİLİM DALI)0000-0001-8217-3471
Türkkan Evrensel(ULUDAĞ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, TIBBİ ONKOLOJİ BİLİM DALI)0000-0002-9732-5340
Pages
—
Publication Date
2022-04-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein, we presented a case who developed acneiform eruptions during cetuximab treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Epidermal growth factor receptor (EGFR) monoclonal antibody inhibitors are used to treat metastatic colorectal cancers.
📊
Key Findings & Data:Cetuximab, an EGFR inhibitor drug, targets specific molecular pathways and does not cause the severe systemic side effects seen in cytotoxic chemotherapy.
💡
Conclusion & Impact:Herein, we presented a case who developed acneiform eruptions during cetuximab treatment.
🔬Design:Case Report
📍Scope:Comprehensive Sample
⚙️Variables:CETUXIMAB · ACNEIFORM ERUPTION · metastatic colorectal cancer

Abstract

Epidermal growth factor receptor (EGFR) monoclonal antibody inhibitors are used to treat metastatic colorectal cancers. Cetuximab, an EGFR inhibitor drug, targets specific molecular pathways and does not cause the severe systemic side effects seen in cytotoxic chemotherapy. Herein, we presented a case who developed acneiform eruptions during cetuximab treatment.

🔖

Cite This Article

Güner, B., Orhan, S. O., Evrensel, T. (2022). Cetuximab-Induced Acneiform Eruption: A Case Report. Turkish Journal of Internal Medicine, Volume: 4 Special Issue. https://doi.org/10.46310/tjim.1071185

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Broadbridge VT, Karapetis CS, Price TJ. Cetuximab in metastatic colorectal cancer. Expert Rev Anticancer Ther. 2012 May;12(5):555-65. doi: 10.1586/era.12.25.
  2. Beech J, Germetaki T, Judge M, Paton N, Collins J, Garbutt A, Braun M, Fenwick J, Saunders MP. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol. 2018 Oct;14(24):2531-41. doi: 10.2217/fon-2018-0187.
  3. Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1834-6. doi: 10.1056/ NEJMe0806778.
  4. Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic toxicity occurring during anti- EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: A systematic review. Clin Colorectal Cancer. 2018 Jun;17(2):85-96. doi: 10.1016/j.clcc.2017.12.004.
  5. Nguyen A, Hoang V, Laquer V, Kelly KM. Angiogenesis in cutaneous disease: part I. J Am Acad Dermatol. 2009 Dec;61(6):921-42; quiz 943-4. doi: 10.1016/j.jaad.2009.05.052.
  6. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007 Feb;56(2):317-26. doi: 10.1016/j. jaad.2006.09.005.
  7. Sipples R. Common side effects of anti-EGFR therapy: Acneform rash. Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):28-34. doi: 10.1016/j.soncn.2006.01.013.